<DOC>
	<DOCNO>NCT02419456</DOCNO>
	<brief_summary>Intravaginal ring ( IVRs ) may offer ideal way deliver antiretroviral ( ARV ) drug prevent HIV infection . This study evaluate pharmacokinetics safety two IVRs contain different dos combination two HIV ARV drug , vicriviroc ( VCV ) ( MK-4176 ) MK-2048 , healthy , HIV-uninfected woman .</brief_summary>
	<brief_title>Pharmacokinetics Two Intravaginal Rings ( IVRs ) Containing Different Dose Strengths Vicriviroc ( MK-4176 ) MK-2048</brief_title>
	<detailed_description>The development safe effective HIV prevention strategy remain global health priority . IVRs currently study method deliver HIV ARV drug woman . This study evaluate pharmacokinetics safety two IVRs contain different dos combination two HIV ARV drug , vicriviroc ( VCV ) ( MK-4176 ) MK-2048 , healthy , HIV-uninfected woman . This study enroll healthy , HIV-uninfected woman , 18 45 year old . Participants randomly assign receive either low dose MK-2048A IVR original dose MK-2048A IVR . Participants receive assign IVR enrollment visit , IVR remove Day 28 . Participants attend study visit screen , enrollment ( Day 0 ) , Days 1 , 2 , 3 , 7 , 14 , 21 , 28 , 29 , 30 , 31 , 35 . Study visit may include medical history review , physical examination , blood collection , pelvic specimen collection , urine collection , counsel adherence assessment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Born female . Note : Participants female birth , identify male , exclude long femaletomale transition therapy . Age 18 45 year ( inclusive ) screening , verify per site SOPs ( standard operating procedure ) Able willing provide write informed consent screen take part study ( MTN028 ) Able willing provide adequate locator information , define site SOPs HIVuninfected , base testing perform study staff screen enrollment ( per applicable algorithm Appendix II protocol ) willing receive result In general good health screen enrollment , determine site Investigator Record ( IoR ) designee At screening , participant state willingness abstain receptive sexual activity ( include penilevaginal intercourse , anal intercourse , receptive oral intercourse , finger stimulation , use sex toy ) 5 day prior enrollment visit duration study participation Per participant report , use effective method contraception enrollment , intend continue use effective method duration study participation . Effective method MTN028 include : hormonal method ( except contraceptive IVRs ) , intrauterine device ( IUD ) insert least 28 day prior enrollment , engage sex exclusively woman , sterilize ( self partner ) , and/or sexually abstinent past 90 day Women age 21 ( inclusive ) must documentation satisfactory Pap within past 3 year prior enrollment consistent Grade 0 accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) , satisfactory evaluation treatment require Grade 1 high Pap result . If otherwise eligible woman documentation recent Pap test , one may perform screen visit . Per participant report screen enrollment , agree participate research study involve drug , medical device , vaginal product duration study participation Per participant report screening , regular menstrual cycle least 21 day menses . Note : This criterion applicable participant report use progestinonly method contraception screening ( e.g. , DepoProvera levonorgestrelreleasing IUD ) participant use continuous combination oral contraceptive pill , absence regular menstrual cycle expect , normal consequence context . At screening , participant state willingness refrain insert nonstudy vaginal product object vagina , include limited , spermicide , female condom , diaphragm , contraceptive IVRs , vaginal medication , menstrual cup , cervical cap ( vaginal barrier method ) , douche , lubricant , sex toy ( vibrator , dildo , etc . ) 5 day prior enrollment duration study participation Participant report follow screen enrollment : History adverse reaction component study product Nontherapeutic injection drug use 12 month prior screen enrollment Postexposure prophylaxis ( PEP ) HIV exposure within 6 month prior enrollment Preexposure prophylaxis ( PrEP ) HIV prevention within 6 month prior enrollment Regular use and/or anticipate regular use period study participation CYP3A inducer ( ) and/or inhibitor ( ) Use and/or anticipate use period study participation femaletomale transition therapy Chronic and/or recurrent candidiasis Gonorrhea , chlamydia and/or syphilis diagnosis 6 month prior enrollment Last pregnancy outcome 90 day less prior screen Currently breastfeed Has hysterectomy Intends become pregnant within next 3 month Has plan relocate away study site area next 3 month Current sexual partner know HIVpositive screen enrollment Reports participate research study involve drug , medical device , vaginal product within 60 day less prior enrollment At screen enrollment , determine IoR/designee , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease Has follow laboratory abnormality screen : Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) Grade 1 high Calculated creatinine clearance le 60 mL/min CockcroftGault formula , creatinine clearance ( female ) mL/min = ( 140 age year ) x ( weight kg ) x ( 0.85 ) /72 x ( creatinine mg/dL ) Hemoglobin Grade 1 high Platelet count Grade 1 high White blood count Grade 2 higher Positive hepatitis B surface antigen ( HBsAg ) test result Positive antihepatitis C virus ( HCV ) test result International normalize ratio ( INR ) great 1.5 Ã— site laboratory upper limit normal ( ULN ) Note : Otherwise eligible participant exclusionary test result ( HIV , hepatitis B virus [ HBV ] , HCV ) retested screen process . If participant retested nonexclusionary result document within 45 day provide informed consent screening , participant may enrol . Pregnant either screen enrollment . Note : A documented negative pregnancy test perform study staff require inclusion ; however selfreported pregnancy adequate exclusion screening/enrollment study . Diagnosed urinary tract infection ( UTI ) screen enrollment . Note : Otherwise eligible participant diagnose UTI screen offer treatment . If within 45 day screen window treatment complete symptom resolve participant may enrol . Diagnosed pelvic inflammatory disease , reproductive tract infection ( RTI ) sexually transmit infection ( STI ) require treatment per current Centers Disease Control Prevention ( CDC ) guideline ( http : //www.cdc.gov/std/treatment/ ) screen enrollment . Note : With exception gonorrhea , chlamydia and/or syphilis , otherwise eligible participant diagnose RTI screen offer treatment . If within 45 day screen window treatment complete symptom resolve , participant may enrol . At enrollment , clinically apparent Grade 1 high pelvic exam finding ( observe study clinician designee ) per Division AIDS Table Grading Severity Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) , Addendum 1 , Female Genital Grading Table Use Microbicide Studies . Note : Cervical friability bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment IoR/designee consider expect nonmenstrual bleeding exclusionary . At screening , severe pelvic relaxation either vaginal wall uterine cervix descend beyond vaginal introitus valsalva maneuver pelvic anatomy compromise ability adequately assess vaginal safety Has condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>